• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Turns Lower; Myomo Shares Jump

    7/8/24 12:07:35 PM ET
    $HLVX
    $IVA
    $LLY
    $MORF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HLVX alert in real time by email

    U.S. stocks traded mixed midway through trading, with the Dow Jones index turning lower on Monday.

    The Dow traded down 0.19% to 39,301.00 while the NASDAQ rose 0.21% to 18,390.4. The S&P 500 also fell, dropping, 0.02% to 5,566.26.

    Check This Out: Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying

    Leading and Lagging Sectors

    Materials shares jumped by 0.4% on Monday.

    In trading on Monday, communication services shares fell by 1.1%.

    Top Headline

    Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.

    Equities Trading UP
                           

    • Morphic Holding, Inc. (NASDAQ:MORF) shares shot up 75% to $55.76 after Eli Lilly agreed to buy the company for $57 per share in cash.
    • Shares of Myomo, Inc. (NYSE:MYO) got a boost, surging 27% to $3.65. after the company issued preliminary second-quarter revenue guidance above estimates.
    • SRIVARU Holding Limited (NASDAQ:SVMH) shares were also up, gaining 39% to $0.2196 after the company announced the deployment of advanced AI tools to manage its lead generation platform.

    Equities Trading DOWN

    • HilleVax, Inc. (NASDAQ:HLVX) shares dropped 87% to $1.8106 after the company announced the NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants.
    • Shares of Wetouch Technology Inc. (NASDAQ:WETH) were down 20% to $2.5250. Wetouch Technologies announced a $15 million stock buyback program to repurchase common stock.
    • Inventiva S.A. (NASDAQ:IVA) was down, falling 10% to $2.6567 after the company issued an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position.

    Also Check This Out: This Analyst With 87% Accuracy Rate Sees Over 35% Downside In Tesla – Here Are 5 Stock Picks For Last Week From Wall Street’s Most Accurate Analysts

    Commodities

    In commodity news, oil traded down 0.6% to $82.66 while gold traded down 0.6% at $2,383.30.

    Silver traded down 0.8% to $31.45 on Monday, while copper fell 0.1% to $4.6485.

    Euro zone

    European shares were mostly higher today. The eurozone's STOXX 600 gained 0.19%, Germany's DAX rose 0.16% and France's CAC 40 fell 0.16%. Spain's IBEX 35 Index rose 0.23%, while London's FTSE 100 rose 0.02%.

    German trade surplus widened to EUR 24.9 billion in May versus a revised EUR 22.2 billion in the prior month.

    Asia Pacific Markets

    Asian markets closed lower on Monday, with Japan's Nikkei falling 0.32%, Hong Kong's Hang Seng Index declining 1.55%, China's Shanghai Composite Index falling 0.93% and India's S&P BSE Sensex declining 0.05%.

    The gauge for Japan's service sector climbed to 47.0 in June from 45.7 in May. Japanese current account surplus increased to JPY 2,849.9 billion in May from JPY 2,010.1 billion in the year-ago month. Foreign exchange reserves in Singapore increased to SGD 503.71 billion in June versus SGD 500.86 billion in the prior month, while Chinese foreign exchange reserves fell by $9.7 billion to $3.222 trillion for June.

    Economics

    Data on consumer credit for May will be released at 3:00 p.m. ET.

    Now Read This: Top 5 Health Care Stocks That May Explode In July

    Get the next $HLVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HLVX
    $IVA
    $LLY
    $MORF

    CompanyDatePrice TargetRatingAnalyst
    Inventiva S.A.
    $IVA
    1/28/2026$18.00Overweight
    Barclays
    Inventiva S.A.
    $IVA
    1/12/2026$12.00Outperform
    Leerink Partners
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Inventiva S.A.
    $IVA
    1/7/2026$12.00Buy
    UBS
    Eli Lilly and Company
    $LLY
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    Eli Lilly and Company
    $LLY
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    Eli Lilly and Company
    $LLY
    11/13/2025$1165.00Sector Outperform
    Scotiabank
    More analyst ratings

    $HLVX
    $IVA
    $LLY
    $MORF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kirk Thomas F bought $5,355 worth of shares (7,437 units at $0.72), increasing direct ownership by 2% to 481,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/24/25 4:04:45 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Crowley Thomas Aloysius Jr. bought $3,233 worth of shares (4,385 units at $0.74), increasing direct ownership by 6% to 75,748 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/21/25 7:22:22 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $57,500 worth of shares (50,000 units at $1.15), increasing direct ownership by 12% to 474,420 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    8/26/25 8:10:16 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $HLVX
    $IVA
    $LLY
    $MORF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Inventiva with a new price target

    Barclays initiated coverage of Inventiva with a rating of Overweight and set a new price target of $18.00

    1/28/26 7:17:30 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Inventiva with a new price target

    Leerink Partners initiated coverage of Inventiva with a rating of Outperform and set a new price target of $12.00

    1/12/26 8:13:43 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS resumed coverage on Eli Lilly with a new price target

    UBS resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $1,250.00

    1/7/26 9:11:47 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HLVX
    $IVA
    $LLY
    $MORF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Finance, & CAO Zakrowski Donald A was granted 584 shares, increasing direct ownership by 21% to 3,423 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:27:28 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP&Pres, LLY USA&Global Capab Yuffa Ilya was granted 4,163 shares, increasing direct ownership by 15% to 32,304 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:26:05 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Pres LLY Oncology&HdCorpBD Van Naarden Jacob was granted 4,866 shares, increasing direct ownership by 22% to 26,626 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/11/26 4:25:13 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HLVX
    $IVA
    $LLY
    $MORF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    Daix (France), New York (United States), February 4, 2025 – Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New York Palace in New York City. Inventiva leadership will also hold one-on-one meetings during the conference. The fireside chat details are as follows: Date: Wednesday, February 11, 2026Tim

    2/4/26 4:00:00 PM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HLVX
    $IVA
    $LLY
    $MORF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HLVX
    $IVA
    $LLY
    $MORF
    SEC Filings

    View All

    Eli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ELI LILLY & Co (0000059478) (Filer)

    2/4/26 7:05:22 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wetouch Technology Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Wetouch Technology Inc. (0001826660) (Filer)

    1/12/26 12:30:28 PM ET
    $WETH
    Computer peripheral equipment
    Technology

    Wetouch Technology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Wetouch Technology Inc. (0001826660) (Filer)

    12/31/25 10:01:52 AM ET
    $WETH
    Computer peripheral equipment
    Technology

    $HLVX
    $IVA
    $LLY
    $MORF
    Financials

    Live finance-specific insights

    View All

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

    INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.   The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into h

    1/21/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly declares first-quarter 2026 dividend

    INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discov

    12/8/25 2:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HLVX
    $IVA
    $LLY
    $MORF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

    SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

    11/14/24 9:36:33 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

    SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

    11/14/24 9:00:08 AM ET
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HLVX
    $IVA
    $LLY
    $MORF
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations